STAAR Surgical Shares Surge After FDA Expands Age Range for EVO ICL Lenses

STAAR Surgical (STAA) shares rose by 8% following an announcement that the US Food and Drug Administration (FDA) has expanded the approved age range for its EVO ICL lens family. The new clearance allows the lenses to be used for patients aged 21 to 60, significantly broadening the company's total addressable market. Previously, the lenses were primarily indicated for a younger demographic, but strong clinical safety data supported the extension to older adults. This move comes as demand increases for refractive surgery alternatives to traditional LASIK procedures. Analysts view this expansion as a major growth catalyst that positions the company to capture a larger share of the ophthalmology market. The positive market reaction reflects investor confidence in the company's ability to scale its technology across wider patient groups.